INTRODUCTION
von Willebrand factor (VWF) is a large multimeric plasma glycoprotein with a dual role in hemostasis by mediating platelet adhesion and aggregation, and stabilizing procoagulant factor VIII. 1, 2, 3 The 178 kb VWF gene is located on the short arm of chromosome 12 (12p12), encoding a protein with a molecular weight ranging from 500 to 20,000 KD. 4, 5 VWF deficiencies and abnormalities caused by mutations of the VWF gene result in von Willebrand disease (VWD), the most common inherited bleeding disorder. 6 VWD can be classified into six types (1, 2A, 2B, 2M, 2N and 3) according to distinct genotypic, clinical and laboratory phenotypic characteristics. 7 Clinically, VWD is characterized by mucocutaneous bleeding and less frequently by hemarthrosis and soft tissue hematomas, depending on the severity of the associated factor VIII (FVIII) deficiency. VWD patients, especially those with type 3 and some type 2 variants, have an increased risk of experiencing potentially life-threatening bleeding. Effective treatment requires correction of the dual defect of hemostasis associated with VWD: 1) abnormal platelet adhesion and aggregation; and 2) defective secondary hemostasis. Desmopressin (1-desamino-8-D-arginine-vasopressin, DDAVP) is used to transiently correct the FVIII/VWF levels by inducing the release of VWF from endothelial cellular compartments. However, in patients with type 3 VWD and in severe forms of types 1 and 2 VWD, DDAVP may not always be effective 8 and may be associated with tachyphylaxis in some DDAVP-responsive patients when closely-spaced infusions are administered, such as during major surgery. Moreover, DDAVP treatment is contraindicated in VWD patients with cardiovascular disease and fluid restriction is necessary to avoid hyponatremia and the risk of seizures, especially in young children.
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From Plasma-derived VWF/FVIII factor concentrates, initially developed for the treatment of hemophilia A, contain large amounts of VWF and are the treatment of choice for DDAVPunresponsive or intolerant patients. [9] [10] [11] [12] [13] Several high purity plasma-derived VWF/FVIII products are available on the market that are effective in the treatment and prevention of bleeds in VWF patients. However, plasma-derived products are limited by plasma donor availability, and the theoretical risk of pathogen transmission cannot be excluded despite viral screening and attenuation measures that have been instituted to minimize such concerns. 14, 15 Plasma-derived VWF/FVIII products also vary in composition depending on the source plasma and the manufacturing process. [16] [17] [18] [19] This variability could lead to excessive FVIII levels in VWD patients, with inherent risk of venous thromboembolism. Furthermore, these concentrates show variable deficiency of ultralarge multimers (ULM) of VWF due to proteolysis. In addition, plasmaderived VWF/FVIII products contain extraneous plasma proteins that may engender allergic responses, which are sometimes severe and may limit their use. 20 Human VWF produced by recombinant technology could offer an important alternative for treatment of VWD by overcoming limitations associated with plasma-derived VWF concentrates. 21 A human rVWF, vonicog alfa, which is synthesized by a genetically engineered Chinese hamster ovary (CHO) cell line coexpressing the VWF and the FVIII genes, has been developed to advance the standard of care for patients with VWD and make the treatment independent from plasma supply.
22
Vonicog alfa is the first rVWF, manufactured in the absence of animal or other human plasma proteins, rendering theoretical the risk of transmission of adventitious agents and other bloodborne pathogens such as prions. In contrast to plasma-derived coagulation factors, no therapeutic
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From protein produced by a recombinant cell line has ever resulted in virus transmission, which is primarily due to the ability to control the recombinant cell line manufacturing environment.
Ultralarge and high molecular weight multimers (HMWM) of VWF are essential for effective platelet plug formation. 18 Plasma-derived VWF concentrates variably lack ULM due to in vivo exposure to plasma ADAMTS13 (a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13) and proteolytic cleavage by granulocyte elastases. [16] [17] [18] [19] In contrast to VWF concentrates derived from plasma, rVWF has no exposure to the human protease ADAMTS13 during the production process, and therefore contains intact HMWM and ULM. 22 The presence of ULM and the higher purity also contribute to a greater specific activity of rVWF measured as VWF:ristocetin cofactor activity (VWF:RCo) relative to VWF:antigen (VWF:Ag).
The pharmacokinetics of rVWF:rFVIII in patients with type 3 VWF have been evaluated in a phase 1 clinical trial, showing a tendency for a longer terminal half-life of rVWF VWF:RCo compared to a plasma-derived VWF:FVIII concentrate and stabilization of endogenous FVIII:C. 23 ULMs present in rVWF were rapidly proteolysed by endogenous ADAMTS13 and no thrombotic events were observed. The current trial was conducted to further assess the PK of rVWF with and without rFVIII infusion and evaluate the safety and hemostatic efficacy of rVWF for the treatment of bleeds in patients with severe type 1, 2 or 3 VWD when administered initially together with rFVIII and subsequently alone provided adequate levels of FVIII:C had been achieved.
PATIENTS, MATERIALS AND METHODS

Subject population
Male 
Trial design and conduct
This phase 3 prospective clinical trial was designed to assess the pharmacokinetics, safety and hemostatic efficacy of rVWF in the treatment of bleeding episodes in adults with severe VWD.
All subjects provided written informed consent prior to any screening procedures. Approval to conduct the trial was granted by the institutional review boards or independent ethics committees of all participating sites. The trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.
Subjects
Subjects were enrolled into one of four arms to receive rVWF for PK assessment and / or 6 months of on-demand bleed treatment (Figure 1 ). Enrollment was conducted across all four treatment arms in parallel. Subjects were allocated to a treatment arm at the investigator's discretion as long as enrollment was still open in the respective arm (it was planned to include at least 7 subjects with type 3 VWD in each PK 50 arm, approximately 12 subjects with severe VWD in the PK 80 + bleed treatment arm [of which at least 6 were to have type 3 VWD], and approximately 7 subjects with severe VWD of any type in the arm for bleed treatment only).
Pharmacokinetics
Pharmacokinetics of rVWF were assessed at 50 IU/kg VWF:RCo and at 80 IU/kg VWF:RCo.
The doses of 50U/kg and 80 U/kg VWF:RCo were selected for PK evaluation as these doses 
Treatment of bleeds
Bleeding episodes were to be treated with an initial infusion of 40-60 IU/kg VWF:RCo rVWF for minor to moderate bleeds such as epistaxis, oral bleeding, or menorrhagia, and up to 80 IU/kg VWF:RCo for major bleeds, which included bleeds such as severe or refractory epistaxis or menorrhagia, gastrointestinal bleeding, central nervous system trauma, hemarthrosis, or posttraumatic hemorrhage. In order to ensure an immediate hemostatic level of FVIII:C, the initial dose of rVWF was to be administered together with rFVIII at a ratio of 1.3:1±0.2 VWF:RCo/FVIII:C, and subsequently without rFVIII as long as therapeutic FVIII:C levels were maintained.
In major bleeding episodes subsequent doses were to be administered every 8 to 12 hours for 3 days to maintain the trough level of VWF:RCo >50 IU/dL and then as deemed necessary by the investigator for up to 7 days. If the VWF:RCo level was above 150 or 200 IU/dL, a planned
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Treatment of each bleed was rated according to a pre-defined 4-point scale (Table 1) based on the actual number of infusions administered to control the bleed versus the treating physician's estimate of the number of infusions required. 24 The primary endpoint was the extent of control of the bleeding episodes, which was defined as the number of subjects with a mean hemostatic efficacy rating score of <2.5. Secondary efficacy outcomes included the number of treated bleeding episodes with a hemostatic efficacy rating of excellent or good and the number of infusions and units of rVWF/rFVIII or rVWF required to control a bleed.
Safety
Safety was evaluated by clinical assessments of adverse events, hematology panels, coagulation panels (including soluble P-selectin and D-dimers), serum chemistry, urinalysis, viral serology, and immunological assessments. Nijmegen modified Bethesda assays were used to determine neutralizing antibodies against VWF:RCo, VWF:collagen binding activity (VWF:CB), FVIII binding activity (VWF:FVIIIB) and FVIII. 26 The presence of total binding anti-VWF antibodies, anti-host cell (CHO) proteins, murine IgG, and anti-human Furin (total Ig) was determined using a proprietary enzyme-linked immunosorbent assay (ELISA) employing polyclonal anti-human Ig antibodies.
27
Test products rVWF is a purified glycoprotein synthesized in a genetically engineered CHO cell line. 28 The manufacturing process of rVWF is based on a cell culture system that expresses both rFVIII (ADVATE) and rVWF; no exogenously added raw materials of human or animal origin are
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Hemostatic and multimer assay methodology
A modified VWF:RCo assay based on the Dade Behring coagulation analyzer (BCS) method was used to determine VWF:RCo activity. 23, 28 VWF:Ag and VWF:CB levels were quantitated using standard sandwich ELISAs employing polyclonal rabbit anti-human-VWF antibodies (DAKO, Denmark) or Collagen Type III (Biozol, Germany), respectively. FVIII activity (FVIII:C) was measured with a one-stage clotting assay (Siemens Coagulation Analyzer CA-7000, Sysmex;
APPT Actin FS, Siemens). VWF multimer patterns were assessed using sodium dodecyl sulfate (SDS)-agarose gel electrophoresis and employing Western blot with luminescence video imaging.
Statistical Methods
For the primary efficacy analysis of the rate of subjects with treatment success, which was defined as a mean efficacy rating score <2.5 (Table 1) , the null hypothesis of a rate of two-sided 95% confidence intervals for the mean (SD), and median and interquartile ranges. The AUC 0-∞ /Dose was also calculated for factor VIII activity (FVIII:C). For crossover PK analysis, AUC 0-∞ /Dose of VWF:RCo of rVWF alone and rVWF:rFVIII were compared by calculating the 90% two-sided confidence interval for the difference of the mean natural logarithms of AUC 0-∞ /Dose between rVWF alone and rVWF:rFVIII. The error variance used to calculate these CIs was obtained from an analysis of variance (ANOVA) model that consisted of fixed effect terms that model the subject effect, the sequence effect, the period effect, and the drug effect. Safety (adverse events) was evaluated descriptively.
RESULTS
Patient disposition and demographics
A total of 49 subjects were enrolled and assessed for eligibility, and 37 subjects were exposed to rVWF during the study (Figure 2 ). Gender was evenly distributed (45.9% male and 54.1% female), and the median age was 37 years (range 18 to 64 years) ( Table 2) .
Hemostatic efficacy
Twenty-two subjects (17 with type 3, 4 type 2A and 1 type 2N VWD) experienced at least one bleeding episode that was treated with rVWF, and 9/31 subjects allocated for bleed treatment did not experience a bleed during the study. A total of 192 bleeding episodes (122 minor, 61 moderate, 7 major/severe, 2 unknown severity) treated with rVWF were assessed for hemostatic efficacy according to a pre-defined 4-point scale ( gastrointestinal tract bleeds) was rated as excellent and treatment of one major bleed in the nasopharyngeal tract was rated good. A median of 2 infusions (range: 1-3) were required to control major bleeds. As expected, the amount of rVWF administered per bleed was generally higher for bleeds of greater severity, however 1 major/severe gastrointestinal tract bleed was controlled after a single infusion of rVWF:rFVIII at a dose of 57.5 IU/kg VWF:RCo and 41.5 IU/kg rFVIII.
In a sub-analysis of mucosal bleeds (menorrhagia, nasopharyngeal or oral cavity; N=100), efficacy for 98% of bleed treatments was rated excellent ( 
Multimer analysis
The presence and in vivo degradation of ULM was established by an observed increase in the median percentage from zero pre-infusion to 30% after 15 minutes post-infusion of rVWF, followed by a substantial decline between 12 and 24 hours. Near-baseline levels were observed in almost all subjects by 96 hours post infusion ( Figure 5 ).
Safety
Eight of a total of 125 adverse events (AE) (6.4%) that were observed during the trial were considered to have a causal relationship to rVWF (Table 6 ). Six of these AEs in four subjects 1 3 were non-serious. One subject experienced mild infusion site paresthesia, moderate dysgeusia and moderate tachycardia, one subject showed a mild ECG T-wave inversion, one subject experienced mild generalized pruritus, and 1 subject had a mild hot flush. One subject experienced two simultaneous serious adverse events (chest discomfort and increased heart rate).
These symptoms improved after 10 minutes of oxygen treatment and the subject fully recovered within three hours and no clinical cardiac symptomatology was observed. This adverse event was assessed as serious due to hospitalization for the purpose of observation. The subject had a history of allergic responses to cryoprecipitate and a pdVWF concentrate. 
DISCUSSION
As the first rVWF formulation, vonicog alfa offers minimization of any potential risk for transmission of adventitious agents and other blood-borne pathogens. In an initial Phase 1 trial in patients with severe VWD, 23 rVWF was shown to be safe with a similar PK profile, a tendency toward a longer VWF:RCo terminal half-life and sustained stabilization of FVIII:C compared to a plasma-derived VWF:FVIII. In the present Phase 3 clinical trial we further investigated the safety of rVWF and evaluated the PK and efficacy using different dosing regimens with and without rFVIII for the treatment of bleeding episodes in subjects with severe type 1, 2 or 3 VWD.
The pharmacokinetic profile of rVWF in subjects with VWD was evaluated in a non-bleeding state, was determined by assessment of VWF:RCo (a surrogate for the platelet-dependent as predicted, no influence of rFVIII was observed. Stabilization of endogenous FVIII was very rapid after administration of rVWF alone, reaching hemostatic levels (>40 IU/dL) within 6 hours (median) and sustained on a high level >70 IU/dL through 48 hours followed by gradual decline in FVIII:C over the 96 hour observation period, but with continued hemostatic levels (>40 IU/dL) up to 72 hours post-infusion.
The lower limit of the 90% CI of the rate of subjects with successful treatment (100%; 90% CI:
87.3 to 100.0%) was well above the pre-defined limit of 65%. A hemostatic efficacy rating of 'excellent' or 'good' was achieved for 100% of treated bleeding events (Clopper-Pearson exact 90% confidence interval: 87.3 to 100.0), which again is significantly higher than the pre-defined 60% limit (a conservative estimate determined for this prospective clinical trial), and is consistent with the reported response rate of 97% with commercial pdVWF:pdFVIII. 32 There were no hemostatic ratings of poor/none during the trial, which compares favorably with results previously reported in a prospective clinical trial of a pdVWF/FVIII concentrate. In that study,
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From for 10/208 bleeds (ranging from mild to major at various sites of bleeding) in VWD type 3 patients received a poor or none efficacy score using a slightly different rating scale. 13 Most bleeding events resolved after one infusion of rVWF:rFVIII or rVWF. Only one bleed (in the genital tract and oral cavity concomitantly, in a type 3 VWD patient) required four infusions, which was the maximum number of infusions administered to treat a bleed during the trial.
Furthermore, while rFVIII was to be administered together with rVWF for the initial infusion to ensure an initial rise to hemostatic levels of rFVIII:C, in the ten treatments where subjects were inadvertently adminstered rVWF alone for the initial infusion, efficacy was rated as excellent. A potential limitation of the present study is the low number of subjects with severe non-type 3
VWD (Type 1 [N=2] and Type 2 [N=6]
). However, as documented previous bleed treatment was prerequisite for inclusion in the study and most bleeds occur in subjects with type 3 VWD, the majority of subjects enrolled either had type 3 VWD, or did not present with a bleed suitable for rVWF treatment during the study. The presence of ULM in rVWF may result in improved platelet and collagen binding and therefore provide more effective treatment outcomes. It has been well established that the size of the highly polymerized VWF multimers directly correlates with their hemostatic activity. 32, 34 More recently, in vitro experiments showed that while highly multimerized rVWF (which have a higher number of collagen and platelet binding sites per molecule) effectively promoted platelet binding and thus have a stronger hemostatic potential, VWF multimers of lower molecular weight showed decreased platelet adhesion properties. 35 In comparison, plasma-derived VWF deficient in ULM were less effective in mediating platelet adhesion to collagen, as reflected by delayed platelet binding kinetics. This advantage may predict efficacy in the very challenging situation of bleeding from gastrointestinal angiodysplasia related to VWD which is historically difficult to manage with VWF replacement therapy. ADAMTS13 degrades the ULM of VWF that is normally synthesized and released by vascular endothelial cells in healthy individuals. In the present trial, the initial increase in median percentage of ULM to 30% after 15 minutes (the earliest time point measured) postrVWF:rFVIII or rVWF treatment was followed by a substantial decline (between 12 and 24 hours) and ULM-reduction to baseline levels by 96 hours, which supports the notion that ADAMTS13 effectively functions to cleave the infused ULM in rVWF. This outcome confirms that the susceptibility of rVWF to ADAMTS13 cleavage allows adequate physiological processing of rVWF upon administration and results in a molecule with low thrombogenicity. 37 However, the enhanced rVWF and FVIII PK profiles suggest that the highly multimerized rVWF molecules may be eliminated more slowly from the circulation and may be more effective in stabilizing FVIII, without resulting in excessively high FVIII:C levels.
rVWF:rFVIII was well tolerated in this trial. AEs were generally mild and transient, and occurred at rates comparable to those observed previously with rVWF-rFVIII or with pdVWF-pdFVIII concentrates. 12, 23, 25 The rate of events considered to be related to treatment was low (6.4%), comprising six non-serious and two serious AEs. The two simultaneous serious events (chest discomfort and increased heart rate), which occurred in a single patient with a history of allergic reactions to cryoprecipitate and a pdVWF concentrate, are known potential risks of factor replacement therapies. No anaphylactic or severe allergic reactions were reported during the trial.
As the ULM were shown to be highly effective in hemostasis, thrombogenic risk was carefully assessed in the clinical development of this product. No thrombotic events observed following treatment with rVWF:rFVIII, neither during the present trial nor in the previous phase 1 trial. 23 In rare cases, alloantibody development against VWF has been observed in patients with type 3 VWD. 38 In the present study, none of the patients developed anti-VWF binding or neutralizing 1 7 antibodies to VWF. Furthermore, as the initial and repeated rVWF PK results are in close agreement in this cohort of subjects with VWD, it can be concluded that there is no evidence of any inhibitory allo-antibodies that would influence the T 1/2 or other PK parameters of rVWF.
In summary, results of this clinical trial provide evidence that rVWF:rFVIII is safe and hemostatically effective in severe VWD patients in a variety of clinical bleeding presentations.
The finding that a single infusion was required for the majority of bleeds may be a reflection of the high ULM content of VWF and the long VWF:RCo T 1/2 relative to plasma-derived VWF/FVIII concentrates which may predict greater efficacy than the plasma-derived concentrates in high risk bleeding situations such as surgery or gastrointestinal bleeding. Finally, the sustained stabilization of endogenous FVIII has the potential to obviate the need for rFVIII after the first infusion when additional infusions are required. 
